MaxCyte Inc.

Last updated September 27, 2026

Organization details

Legal name
MaxCyte Inc.
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
8731 — Services-Commercial Physical & Biological Research
Jurisdiction of incorporation
Delaware
Headquarters city
Rockville
Headquarters state / province
Maryland
Headquarters country
United States
Fiscal year end
December
Ticker symbol
MXCT
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001287098
EIN
52-2210438
Wikidata ID
Q30290314

Board of directors

Chief executives

Douglas Doerfler · President and CEO
Dates unknown
Maher Masoud · President and CEO
Dates unknown

Director election results

Annual meeting of June 22, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 7 other boards. 5 are in the same sector.

Network of MaxCyte Inc.'s board connections ALX Oncology Holdings Inc. ALX Oncology Holdings... Aldeyra Therapeutics Inc. Aldeyra Therapeutics I... BioAge Labs Inc. BioAge Labs Inc. Certara Inc. Certara Inc. Codexis Inc. Codexis Inc. LB Pharmaceuticals Inc LB Pharmaceuticals Inc Novavax Inc. Novavax Inc. Cynthia Collins Cynthia Collins Rekha Hemrajani Rekha Hemrajani Richard Douglas Richard Douglas MaxCyte Inc.
Shared director Other board Same sector

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$8,316
1 sale by 1 insider
Date Insider Transaction Shares Price Value
Jun 17, 2026 John Joseph Johnston Director Grant or award +30,421 — —
Jun 17, 2026 Rekha Hemrajani Director Grant or award +30,421 — —
Jun 17, 2026 Stanley C. Erck Director Grant or award +30,421 — —
Jun 17, 2026 Richard Douglas Director Grant or award +30,421 — —
Jun 17, 2026 Cynthia Collins Director Grant or award +30,421 — —
Jun 17, 2026 William W. Brooke Director Grant or award +30,421 — —
Jun 17, 2026 Patrick J. Balthrop Director Grant or award +30,421 — —
Jun 17, 2026 Yasir B. Al-Wakeel Director Grant or award +30,421 — —
Apr 15, 2026 Ahuja Parmeet Officer (Chief Financial Officer) Grant or award +187,500 — —
Mar 27, 2026 Maher Masoud Director, Officer (President and CEO) Grant or award +300,000 — —
Mar 17, 2026 Douglas J. Swirsky Officer (CHIEF FINANCIAL OFFICER) Open-market sale −10,142 $0.82 $8,316
Aug 13, 2025 Douglas J. Swirsky Officer (CHIEF FINANCIAL OFFICER) Open-market purchase +50,000 $1.29 $64,500
Aug 13, 2025 Maher Masoud Director, Officer (President and CEO) Open-market purchase +75,000 $1.37 $102,750
Aug 13, 2025 Stanley C. Erck Director Open-market purchase +100,000 $1.37 $137,000
Aug 13, 2025 Richard Douglas Director Open-market purchase +80,000 $1.39 $111,200

Organizations in the same sector, closest in location and size first.

Questions about MaxCyte Inc.

Who is the CEO of MaxCyte Inc.?

Douglas Doerfler is MaxCyte Inc.'s President and CEO.

How many directors are on MaxCyte Inc.'s board?

MaxCyte Inc.'s board has 11 directors: Art Mandell, Cynthia Collins, Douglas Doerfler, John Joseph Johnston, Maher Masoud, Patrick J. Balthrop, Rekha Hemrajani, Richard Douglas, Stanley C. Erck, William W. Brooke and 1 other.

Are MaxCyte Inc. insiders buying or selling shares?

Over the last 12 months, MaxCyte Inc. insiders made no open-market purchases and sold $8,316 of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="maxcyte-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.